TuisSGIOY • OTCMKTS
Shionogi 4 ADR Representing Ord Shs
$11,12
Na ure:
$11,12
(0,00%)0,00
Toe: 27 Sep., 16:13:27 GMT-4 · USD · OTCMKTS · Vrywaring
GLeaf-logoKlimaatleierVSA-gelyste effekHoofkantoor in JP
Vorige sluiting
$11,24
Dagwisseling
$10,51 - $11,23
Jaarwisseling
$9,33 - $13,67
Markkapitalisasie
1,90 bn JPY
Gemiddelde volume
42,60 k
CDP-klimaatveranderingtelling
A
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(JPY)Jun. 2024J/J-verandering
Inkomste
97,59 mjd-10,73%
Bedryfskoste
55,03 mjd10,94%
Netto inkomste
30,64 mjd-28,02%
Netto winsgrens
31,39-19,39%
Wins per aandeel
EBITDA
33,03 mjd-35,20%
Effektiewe belastingkoers
17,02%
Totale bates
Totale aanspreeklikheid
(JPY)Jun. 2024J/J-verandering
Kontant en korttermynbeleggings
281,96 mjd-2,46%
Totale bates
1,45 bn6,23%
Totale aanspreeklikheid
157,74 mjd-8,07%
Totale ekwiteit
1,29 bn
Uitstaande aandele
283,49 m
Prys om te bespreek
0,00
Opbrengs op bates
4,90%
Opbrengs op kapitaal
5,48%
Netto kontantverandering
(JPY)Jun. 2024J/J-verandering
Netto inkomste
30,64 mjd-28,02%
Kontant van bedrywe
33,50 mjd6,74%
Kontant van beleggings
-90,85 mjd-161,40%
Kontant van finansiering
-24,83 mjd-7,63%
Netto kontantverandering
-76,13 mjd-277,88%
Beskikbare kontantvloei
-81,81 mjd-634,02%
Meer oor
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Gestig
17 Mrt. 1878
Werknemers
4 959
Search
Vee soektog uit
Maak soekkassie toe
Google-programme
Hoofkieslys